Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of “Buy” from Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have received a consensus rating of “Buy” from the six research firms that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $10.92.

A number of research firms recently issued reports on VOR. JMP Securities reaffirmed a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a research report on Friday, September 6th. Barclays lowered their price target on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a report on Friday, September 6th.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds have recently added to or reduced their stakes in VOR. Renaissance Technologies LLC raised its position in shares of Vor Biopharma by 48.0% in the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after purchasing an additional 160,642 shares during the period. Rosalind Advisors Inc. acquired a new position in Vor Biopharma in the 3rd quarter valued at about $54,000. Vanguard Group Inc. raised its holdings in Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after acquiring an additional 69,436 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vor Biopharma during the second quarter worth approximately $63,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Vor Biopharma during the first quarter worth approximately $126,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Stock Down 4.2 %

Shares of VOR opened at $0.80 on Monday. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $3.14. The stock has a market capitalization of $55.05 million, a P/E ratio of -0.46 and a beta of -0.41. The company has a 50 day moving average of $0.80 and a 200-day moving average of $1.10.

Vor Biopharma (NYSE:VOR) last announced its earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). On average, sell-side analysts anticipate that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.